Arbutus Biopharma Corp: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 7, 2018 and accepted by EDGAR at Nov 7, 2018, 17:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-07-01 to 2018-09-30 | $1.6m | us-gaap:Revenues |
| Revenue | 9 months2018-01-01 to 2018-09-30 | $4.3m | us-gaap:Revenues |
| Research and development | 3 months2018-07-01 to 2018-09-30 | $16.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2018-01-01 to 2018-09-30 | $46.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$32.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | −$72.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-07-01 to 2018-09-30 | $0 | us-gaap:InterestExpense |
| Interest expense | 9 months2018-01-01 to 2018-09-30 | $104.0k | us-gaap:InterestExpense |
| Income tax | 3 months2018-07-01 to 2018-09-30 | −$4.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2018-01-01 to 2018-09-30 | −$4.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-07-01 to 2018-09-30 | −$24.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | −$38.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | −$0.84 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2018-07-01 to 2018-09-30 | −$13.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | −$50.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2018-07-01 to 2018-09-30 | $237.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Capital expenditure | 9 months2018-01-01 to 2018-09-30 | $911.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-09-30 | $21.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $144.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $245.4m | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $12.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $30.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-09-30 | $215.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-18-013909. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.